(MPD) plans. METHODS: Fifty patients were randomly selected from a database of 18,000 Medicare-eligible patients provided by a pharmacy benefits management company. Each patient's medication history from January-June 2007 was used to generate their medication profile. Each profile was entered into the Medicare website and the EAC were calculated. For each patient the lowest, mean, and highest EAC were obtained for both 2007 and 2008 The study objectives were to describe the characteristics and quality of health economics (including pharmacoeconomics) evaluation research studies related to Zimbabwe. METHODS: A literature review was conducted to identify health economic evaluation articles. Health economics evaluation, PUBMED, MEDLINE, HealthSTAR, EconLit, and Psychinfo databases and sociological and dissertation abstracts were used to search economic analyses. Only original applied economic evaluations addressing a health-related topic related to Zimbabwe and published in peer reviewed journals in the English language were included. Two reviewers independently evaluated and scored each article in the final sample. RESULTS: The 25 identified articles, published between 1987 and 2005, appeared in 13 different journals (based mostly outside of Zimbabwe). On average, each article was written by three authors, who had mostly medical/clinical training. The number of articles peaked between 1993 and 1997. Based on a 1 to 10 scale, with 10 indicating the highest quality, the mean quality score for all studies was 5.36 (SD = 1.57) and about one-third of the articles were of poor quality (score < 4). The quality of articles was statistically significantly related (p < 0.10) to the country of journal (non-Zimbabwe = higher), type of publication (nonmedical = higher), number of authors (more authors = higher), years of publication (more recent = higher), and primary health intervention (services higher than pharmaceutical interventions). The quality of the articles was not significantly related to the country of current residence of the primary authors, sample size, primary training of the first author, main objective of the study, and type of data (primary vs secondary). CONCLUSION: The results of the study indicated that the use of health economics (including pharmacoeconomics) evaluation research in Zimbabwe is limited and about one-third of published articles were of poor quality. More and better quality health economics research in Zimbabwe is warranted.
PHP49 FRAMEWORK AND METHODOLOGY TO IDENTIFY AND ASSESS PHARMACIST-SENSITIVE OUTCOMES IN COLLABORATIVE MEDICATION MANAGEMENT
Bajcar J, Machado M, Einarson TR University of Toronto, Toronto, ON, Canada OBJECTIVE: To develop a theoretical framework and process to define and identify pharmacist-sensitive outcomes for chronic diseases and propose how these can be operationalized within practice, policy, and research. METHODS: A collaborative medication management framework was developed to provide a platform for identifying outcomes sensitive to pharmacists' contribution to patient's care. Potential indicators for specific pharmacist's roles identified were: supporting medication-prescribing practice; medication-taking practice; and medication-related information transfer. Clinical indicators of potential impact on patient's outcomes were noted. The framework was used to structure gathering, selecting, and processing of literature-based information. We searched IPA, Medline, and Embase (inception-2006) to identify research describing the impact of pharmacists' patient-care interventions. Two independent reviewers identified articles, then extracted data; results were compared and settled through consensus. Articles were grouped by disease. Outcomes/ indicators were categorized as definitely sensitive, probably sensitive, probably not sensitive, or definitely not pharmacistsensitive. Data extracted included intervention type, patient numbers, demographics, study characteristics, instruments used, data compared, and outcomes. Where sufficient, data were combined in a random-effects meta-analysis. Study quality was assessed using Downs-Black scale. RESULTS: The framework and the methodology developed are effective in synthesizing and interpreting literature data to identify pharmacist-sensitive outcomes. Average study quality was 62% Ϯ 11% ("fair"). Significant impacts were found on reducing glycosylated hemoglobin (0.62% Ϯ 0.29%; N = 2247; k = 16; P = 0.03) and systolic blood pressure (6.9Ϯ3.5 mmHg; N = 2246; k = 13; P = 0.047). Non-sensitive were diastolic blood pressure (3.6 Ϯ 1.9 mmHg; N = 2246; k = 13; P = 0.06), quality of life (1/8 significant) and compliance (5/13 significant). CON-CLUSION: Pharmacist-sensitive outcomes identified to date are for diabetes and hypertension (in progress are asthma-COPD, congestive heart failure, mental illnesses and arthritis). More research studies are required to verify the significance of findings. Pharmacist-sensitive outcomes is an underdeveloped concept. Current studies primarily assess clinical outcomes and few measure indicators that are more proximal to a pharmacist intervention.
